This retrospective observational study will analyse demographic, clinical and treatment-related data of patients with non-squamous non-small cell lung cancer (NSCLC) who had reached >/= 9 months of progression-free survival after Avastin (bevacizumab)-based first-line therapy. Data will be collected for approximately 9 months.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Non-squamous non-small cell lung cancer (NSCLC) treated with first-line Avastin-based therapy
• Progression-free survival of >/= 9 months reached

Exclusion Criteria:

• N/A

Non squamous NSCLC patients treated with bevacizumab-based first line therapy and PFS >/= 9 months